Up­dat­ed: No­vo Nordisk's semaglu­tide in­jec­tion re­duces car­dio­vas­cu­lar events by 20% in vast SE­LECT tri­al

No­vo Nordisk’s semaglu­tide in­jec­tion re­duced ma­jor ad­verse car­dio­vas­cu­lar events by 20% in obese or over­weight pa­tients with­out di­a­betes, fur­ther bol­ster­ing the case for more wide­spread use of the game-chang­ing GLP-1.

No­vo Nordisk said Tues­day morn­ing that the vast SE­LECT tri­al in­ves­ti­gat­ing semaglu­tide hit its pri­ma­ry end­point: the re­duc­tion in ma­jor ad­verse car­dio­vas­cu­lar events (MACE), which in­cludes car­dio­vas­cu­lar death, non-fa­tal my­ocar­dial in­farc­tion or non-fa­tal stroke, com­pared with place­bo. It en­rolled 17,604 adults who were 45 years or old­er, over­weight or obese, and had a di­ag­no­sis of car­dio­vas­cu­lar dis­ease. There were 1,270 first MACEs in the study, ac­cord­ing to the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER